Prev Arrow Stocks

Moderna Inc. ($MRNA) Stock Forecast: Up 5.1% Today

Morpher AI identified a bullish signal. The stock price may continue to rise based on the momentum of the good news.

What is Moderna Inc.?

Moderna (NASDAQ: MRNA) is a biotechnology company known for its innovative mRNA technology, particularly in the development of COVID-19 vaccines. The overall market sentiment towards MRNA has been positive due to its role in the fight against the pandemic.

Why is Moderna Inc. going up?

MRNA stock is up 5.1% on Jul 10, 2025 18:41

  • Moderna's stock (MRNA) saw a notable uptrend subsequent to receiving full approval from the FDA for its COVID-19 vaccine for children aged 6 months and above.
  • The extended approval for this younger age demographic suggests a wider market scope for Moderna's vaccine, fostering enhanced investor confidence and propelling the stock price upwards.
  • This favorable development underscores Moderna's ongoing success in diversifying its vaccine portfolio and combatting the global health crisis, contributing to the bullish trend in the stock today.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months - Moderna ( NASDAQ:MRNA )

The FDA fully approves Moderna's Spikevax for children six months to 11 years at high risk of COVID-19. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On The U.S.

https://www.benzinga.com/news/fda/25/07/46351929/fda-grants-complete-approval-to-modernas-covid-19-vaccine-for-children-as-young-as-6-months

0 News Article Image FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months - Moderna  ( NASDAQ:MRNA )

Company News for Jul 9, 2025

Companies in The News Are: FCX, MRNA, NRG, HES ...

https://www.zacks.com/stock/news/2568903/company-news-for-jul-9-2025

1 Missing News Article Image Company News for Jul 9, 2025

Moderna Inc. Price History

24.05.2025 - MRNA Stock was up 5.4%

  • Moderna's stock had a strong bullish movement today, closing at $25.90 with a +1.97% shift.
  • The bullish movement could be attributed to positive developments related to the company's pipeline or vaccine distribution.
  • Despite the bullish movement, there are indications that deep-pocketed investors have taken a bearish stance on Moderna, as revealed by options records. This contrasting sentiment from big money investors could be due to concerns about future growth prospects or market conditions.

10.06.2025 - MRNA Stock was up 5.1%

  • Moderna's stock (MRNA) saw a notable uptrend subsequent to receiving full approval from the FDA for its COVID-19 vaccine for children aged 6 months and above.
  • The extended approval for this younger age demographic suggests a wider market scope for Moderna's vaccine, fostering enhanced investor confidence and propelling the stock price upwards.
  • This favorable development underscores Moderna's ongoing success in diversifying its vaccine portfolio and combatting the global health crisis, contributing to the bullish trend in the stock today.

10.06.2025 - MRNA Stock was up 5.4%

  • Moderna (MRNA) stock showed significant bullish movement.
  • The positive market trend may be linked to potential developments in Moderna's vaccines and therapeutics pipeline.
  • Investors are likely responding favorably to updates on Moderna's ongoing research and development activities, leading to an increase in stock price.
  • The bullish movement could also be influenced by general market positivity and investor trust in the biotechnology industry.

02.06.2025 - MRNA Stock was up 5.6%

  • Moderna's stock (MRNA) witnessed a noticeable upward trend in the market today.
  • The favorable market response is linked to the recent announcement regarding Moderna's mRNA flu vaccine, mRNA-1010, displaying 26.6% higher efficacy in adults aged 50 and above compared to conventional flu shots.
  • Investors responded positively to the encouraging vaccine trial results, signaling Moderna's potential to maintain its forefront position in mRNA-based vaccine research.
  • This development highlights Moderna's ongoing advancements in the healthcare sector, bolstering investor confidence and contributing to the stock's uptick.

21.04.2025 - MRNA Stock was down 8.1%

  • Despite the FDA's stricter standards for COVID-19 shots, MRNA and PFE stocks saw a jump. This could indicate that investors are still optimistic about the companies' abilities to navigate regulatory challenges.
  • The options frenzy on Moderna showed a bearish trend, with a majority of traders exhibiting bearish tendencies. This could have contributed to the overall negative movement in MRNA stock today.
  • The conflicting signals from different sources might have caused confusion among investors, leading to increased selling pressure on MRNA shares.

12.05.2025 - MRNA Stock was down 5.1%

  • Moderna (MRNA) saw a decline, potentially due to profit-taking following a period of strong performance.
  • Positive outcomes from Novavax's COVID-flu combination shot trial may have diverted investor attention from Moderna temporarily.
  • A legal win against Alnylam Pharmaceuticals in a patent dispute could have been overshadowed by broader market sentiment, impacting Moderna's stock negatively.
  • Mirum Pharmaceuticals' financial results and subsequent stock movements could have influenced overall investor outlook on biotech stocks, including Moderna.

08.06.2025 - MRNA Stock was up 5.3%

  • MRNA stock rose significantly following the CDC's decision to broaden recommendations for RSV vaccine to high-risk adults aged 50-59.
  • The expanded guidance is anticipated to enhance the market accessibility of Moderna's RSV vaccine, mResvia, increasing investor confidence and boosting the stock price.
  • This favorable development showcases Moderna's ongoing success in utilizing its advanced technology to address crucial healthcare needs, further establishing its position as a prominent player in the biotech industry.

06.05.2025 - MRNA Stock was up 5.3%

  • Moderna (MRNA) witnessed a notable bullish movement in the market recently.
  • This upward trend could be linked to a recent court ruling stating that SM-102, a crucial ingredient in Moderna's Spikevax COVID-19 vaccine, does not violate Alnylam Pharmaceuticals' mRNA patents. This legal victory likely boosted investor confidence in Moderna's vaccine technology and market position.
  • Furthermore, reports of significant financial institutions taking bearish positions on Moderna may have presented a short-term buying opportunity for traders, resulting in increased demand for the stock and contributing to its bullish movement.
  • Taken together, the positive legal outcomes and strategic trading activities are believed to have driven Moderna's stock price higher on the given day.

27.04.2025 - MRNA Stock was up 5.3%

  • Moderna's bullish movement results from the company's seeking FDA approval for an updated COVID-19 vaccine targeting the LP.8.1 variant, prevalent in the U.S., showcasing its proactive response to new COVID-19 strains and market competitiveness.
  • Despite an initial setback due to the withdrawal of the FDA filing for the COVID-Flu combo shot, the positive news about seeking approval for an updated COVID-19 vaccine overshadowed the issue, contributing to the stock's positive movement.
  • Moderna's stock surged alongside Pfizer's and BioNTech's following the FDA's stricter standards for COVID-19 shots, reflecting investor confidence in these companies' capabilities to overcome regulatory hurdles and provide solutions for high-risk populations.

03.05.2025 - MRNA Stock was up 5.1%

  • Moderna's stock surged after the company announced FDA clearance for its new COVID-19 vaccine, mNEXSPIKE, specifically tailored for seniors and at-risk individuals.
  • The new vaccine demonstrated significantly higher efficacy compared to the company's original vaccine, showcasing a positive outlook for Moderna's vaccine portfolio.
  • The cancellation of the government funding contract for Moderna's bird flu shot did not seem to deter investor confidence, as the focus remained on the promising developments in the COVID-19 vaccine sector.
  • Overall, Moderna's bullish movement can be attributed to the positive news surrounding the efficacy and FDA clearance of its new COVID-19 vaccine, overshadowing the setbacks in other vaccine projects.

16.04.2025 - MRNA Stock was up 7.2%

  • Moderna's stock surged significantly today, despite signs of bearish options activity.
  • The divergence between short-term speculative views and long-term investor confidence in Moderna's growth potential may explain this stock movement.
  • Positive updates on Moderna's vaccine progress or a positive market sentiment towards the biotech sector could have fueled this bullish momentum, overshadowing bearish options signals.

16.04.2025 - MRNA Stock was up 7.2%

  • Despite the options frenzy and bearish moves by financial giants, Moderna's stock saw a strong bullish movement today.
  • The unusual options trades and the majority of traders showing bearish tendencies did not align with the actual market performance of Moderna.
  • This discrepancy could be attributed to unexpected positive news or developments regarding Moderna's vaccine technology or pipeline, leading to increased investor confidence and driving the stock price higher.
  • It's essential for traders to consider all available information and not solely rely on options activity when making investment decisions, as market movements can sometimes defy conventional expectations.
i
Disclaimer
Morpher is not liable for the content of the AI investment insights. Like most GPT-powered tools, these summaries may contain AI hallucinations and inaccurate information. Morpher is not presenting you with any investment advice. All investments involve risk, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. These summaries do not constitute investment advice.